SecBot SecBot

HYPR

Hyperfine, Inc.
Nasdaq· Electromedical & Electrotherapeutic Apparatus· Inc. DE· CIK 0001833769 Healthcare & Medical Devices
$0.7230 −0.00 (−0.14%)
Oct 26 4:00 PM ET · prev $0.7240
Market cap
$77.0M
Micro cap
Consensus
Buy
89% Buy or better · 9 analysts
Median target
$2.00
+177% · range $1.60–2.50
Next earnings
Nov 9
in 13 days · EPS est. −$0.08
1 year
−42.2%
from $1.25 · Oct 27
30 days
−13.5%
from $0.8360
52-week range
$0.7230–1.87
at the low
Avg volume 20D
1.24M
Oct 8 spike 11.06M
Short interest
🔒 Subscribers only
Insider net
−$91.9K
0 buyers · 2 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read BULLISH 1 report · 90 days
Balance 0 bearish · 1 bullish oldest → newest, height = score
Avg score ·Next Earnings date, Nov 9, 2026

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $91.9K.

  • InstitutionsBULLISH

    Q2 2026: 11 added (0 new), 5 trimmed or exited.

  • AnalystsBULLISH

    8 of 9 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.090 → −$0.080 over 90 days. 2 up, 0 down in 30 days.

  • TrendDOWNTREND

    12% below its 50-day average. New closing low $0.7230 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED4,673,087$6.3M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED1,960,811$2.6M
STATE STREET CORPDOUBLED1,016,970$1.4M
RENAISSANCE TECHNOLOGIES LLCADD945,836$1.3M
NORTHERN TRUST CORPDOUBLED633,054$854.6K
Bank of New York Mellon CorpDOUBLED310,405$419.0K
WELLS FARGO & COMPANY/MNDOUBLED73,992$99.9K
Centiva Capital, LPDOUBLED63,035$85.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 89% rate it Buy or better
Strong Buy3Buy5Hold1Sell0Strong Sell0
12-month targets · 3 analysts

Price is below the lowest target. Median implies +177%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 22, 2026BTIG
REITERATE
REITERATEBuy
Sep 14, 2026BTIG
REITERATE
REITERATEBuy
Aug 10, 2026B. Riley Securities
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$91.9K
sold · 2 insiders
DateInsiderTypeValue
Aug 24, 2026
HALE BRETT
CFO and CAO
SELL$6.3K
Aug 24, 2026
TEISSEYRE THOMAS
Chief Operating Officer
SELL$6.3K
Jun 3, 2026
Wolterman Dan
Director
AWARD52,600 sh
May 26, 2026
TEISSEYRE THOMAS
Chief Operating Officer
SELL$10.0K
May 26, 2026
HALE BRETT
CFO and CAO
SELL$10.0K
May 22, 2026
ROTHBERG JONATHAN M
Director
AWARD157,700 sh
May 22, 2026
Dahldorf John T
Director
AWARD157,700 sh
May 22, 2026
Wolterman Dan
Director
AWARD157,700 sh

Earnings setup

Estimates
Nov 9
reports in 13 days
−$0.08
EPS estimate, this quarter
+11%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.08-$0.08–-$0.08+0.0%$5.8M
Next Q-$0.08-$0.08–-$0.08-6.7%$6.6M
Current FY-$0.34-$0.34–-$0.34+1.4%$20.2M
Next FY-$0.32-$0.32–-$0.32+0.0%$26.3M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 8, 2026 SEC
Hyperfine reported record preliminary Q3 2026 revenue of approximately $6.0M, up 53% sequentially from Q2 2026, and…
8-K — Impact 6/10
Sep 24, 2026 Listing status
Listing Status: HYPR — Deficient (was Normal)
Hyperfine, Inc. - Class A Common Stock | Nasdaq Financial Status Indicator N → D
Aug 24, 2026 Insider
HALE BRETT sold 7,345 shares
CFO and CAO @ $0.8540 ($6.3K)
Aug 24, 2026 Insider
TEISSEYRE THOMAS sold 7,345 shares
Chief Operating Officer @ $0.8540 ($6.3K)
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
4,673,087 shares ($6.3M)
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — DOUBLED
1,960,811 shares ($2.6M)
Jun 3, 2026 Insider
Wolterman Dan was granted 52,600 shares
Director
May 22, 2026 SEC
Hyperfine's S-3 shelf registration (File No. 333-295807) became effective on May 21, 2026, enabling the resale of…
EFFECT — Impact 4/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent

SecBot reports

5 filings · 1 bullish · 1 bearish · 3 neutral
All HYPR filing & press-release reports (5)